Priv.-Doz. Dr. Matthias Pinter, PhD, Universitätsklinik für Innere Medizin III, Wien, präsentiert beim ILC 2019 Ergebnisse zur PD-1-Inhibition beim Leberzellkarzinom und diskutiert Daten zur Sequenz Sorafenib -> Regorafenib sowie eine mögliche HCC-Risiko-Reduktion durch COX-Inhibitoren.

Abstracts, die im Video erwähnt werden:

PS-136 Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis
Atsushi Hiraoka, Japan

PS-142 Analysis of sorafenib-regorafenib sequential therapy in patients with advanced hepatocellular carcinoma using baseline date of sorafenib
Sae Yumita

PS-138 PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort
Matthias Pinter, Austria

PS-116 Use of cyclooxygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nested case-control study using a nationwide population-based data
Sohn Won, Korea, Rep. of South

SAT-490 No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort
Anais Vallet Pichard, France

International Liver Congress 2019, 10-14-4.19, Wien